CervoMed Strengthens Leadership With Appointment Of Matthew Winton, Ph.D., As Chief Commercial And Business Officer

CervoMed Inc., a clinical-stage company developing treatments for age-related neurologic disorders, has announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton brings nearly 20 years of experience in the global biotechnology industry, with a strong track record in leading organizations through scientific innovation, growth, and market expansion. John Alam, M.D., Chief Executive Officer of CervoMed, welcomed Dr. Winton, emphasizing the importance of his appointment as the company advances into late-stage Phase 3 development. 

Dr. Alam noted that Dr. Winton’s extensive commercial expertise and experience in building patient-focused healthcare franchises in the central nervous system (CNS) space will be instrumental in preparing for the potential launch of neflamapimod for patients with dementia with Lewy bodies (DLB). Dr. Winton expressed enthusiasm about joining CervoMed and contributing to its mission. He highlighted the unmet medical need in DLB and the opportunity to transform treatment in this area. 

He stated, “I am very excited to work alongside this passionate and driven team of healthcare pioneers who are endeavoring to fundamentally change the way DLB is treated. I look forward to building the foundation for the successful commercialization of neflamapimod, as well as forging innovative industry partnerships as CervoMed prepares for the next stage of corporate growth.”

Prior to joining CervoMed, Dr. Winton served as Chief Operating Officer at Inozyme Pharma, where he managed commercial readiness and strategic operations, supporting the company’s successful acquisition by BioMarin Pharmaceuticals. He also spent nearly a decade at Biogen in senior leadership roles, including Senior Vice President and Head of the U.S. Multiple Sclerosis Franchise and Vice President and Head of the U.S. Spinal Muscular Atrophy Franchise. 

In these roles, he built and scaled commercial organizations, managed multi-billion-dollar neurology portfolios, and guided the launch and growth of SPINRAZA™, the first approved treatment for spinal muscular atrophy (SMA). Earlier in his career, Dr. Winton advised biotechnology and pharmaceutical clients on commercialization strategy at Campbell Alliance and Leerink Swann Strategic Advisors.

Dr. Winton holds a Ph.D. in Neuroscience from the Université de Montréal, an M.B.A. in Health Sector Management from Boston University, and a B.Sc. in Biology and Psychology from York University. He completed a postdoctoral fellowship at the Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania. In connection with his appointment, CervoMed granted Dr. Winton an option to purchase 75,000 shares of the company’s common stock at an exercise price of $8.62, the closing price on the grant date of October 6, 2025. 

The option will vest in 36 equal monthly installments over three years, contingent upon continued employment. The award was approved by the company’s compensation committee as an inducement material to Dr. Winton joining CervoMed, in accordance with Nasdaq Listing Rule 5635(c)(4). With Dr. Winton joining the leadership team, CervoMed strengthens its commercial and business capabilities as it prepares to advance neflamapimod through late-stage development and ultimately bring a potential treatment to patients with DLB.